Boehringer begins enrolment in Phase II BALANCE-CF1 trial

Boehringer’s BI 1265162 prevents the absorption of sodium. Credit: Boehringer Ingelheim.



  • Boehringer begins enrolment in Phase II BALANCE-CF1 trial